Search

You searched for "prostatic"

526 results found

Wit, wine, whisky and wisdom – Prestonfield’s Burns Supper returns for 2026 in aid of Prostate Scotland

20 November 2025
Tickets are now on sale for Prestonfield’s annual Burns Supper, taking place on Thursday 22 January 2026 at the spectacular Prestonfield House in Edinburgh. This enchanting evening promises an opulent blend of wit, wine, whisky and wisdom, all in support...

Intermittent vs. continuous hormonal therapy for metastatic prostate cancer

1 July 2014 | | URO - Urologic Oncology
Continuous androgen deprivation therapy (cADT) is the standard management for metastatic prostate cancer (mPCa). Intermittent androgen deprivation therapy (iADT) is sought to have better quality of life (QoL) and adverse events profile during off-treatment period. This multicentre European randomised study...
Fast Facts: Prostate Cancer book cover.

Fast Facts: Prostate Cancer

3 March 2021 | | URO - Urologic Oncology
I have read this book since my SHO days, when the first edition was published in 1996, and still enjoy reading every new edition. This is a concise, pocket-sized book which is designed to provide a rapid update on what...
An Insider’s Perspective of Prostate Cancer book cover image.

An Insider’s Perspective of Prostate Cancer – Understanding Effects, Management Options and Consequences

27 April 2023 | | URO - Urologic Oncology
This deceptively small paperback punches way above its weight compared to some of the existing hefty tomes on prostate cancer. It is an admirable effort at delivering content pitched at both the lay reader as well as the medical graduate....

Vasectomy and prostate cancer

1 March 2017 | | URO - Andrology, URO - Urologic Oncology
Urologists are always trying to identify risk factors for prostate cancer (CaP). This population-based study is from Ontario, Canada. The study sample comprised nearly 300,000 men who underwent vasectomy and an equal number who did not. The primary outcome was...

Focal therapy trials

6 November 2020 | | URO - Urologic Oncology
Men with localised prostate cancer have traditionally required whole gland treatment involving radical prostatectomy or radical radiation treatment, independent of disease location and size. Increasing evidence supports the use of active treatment only in those men diagnosed with prostate cancer...

MOWOOT II Intestinal Transit Management System

1 November 2020 | Research & Development
MOWOOT II is an intermittent colonic exo-peristaltic therapy system for intestinal transit disorders, such as slow transit constipation. MOWOOT II utilises advanced pneumatic technology to treat and prevent chronic constipation without laxatives, enemas...

Managing Sexual Side Effects After Prostate Cancer: A Patient & Therapist Perspective

20 January 2026
@6:00 - 7.15pm

Fusion Bx 2.0 targeted prostate biopsy solution receives CE Mark

4 November 2019 | Research & Development
Focal Healthcare, an innovator of image-guided prostate cancer technology, has received CE Mark for its Fusion BxTM 2.0 prostate fusion biopsy solution.

Prostate Cancer UK warns of over 8,600 ‘missing men’ as referrals drop by 52,000

5 May 2021 | Research & Development, COVID-19
The Covid-19 pandemic has led to around 52,000 (28%) fewer urgent prostate cancer referrals in England alone, according to statistics shared by Prostate Cancer UK. It’s estimated that more than 8,600 fewer men started treatment for...

KOELIS Trinity® - Accuracy in prostate care

30 November 2021 | Research & Development
KOELIS Trinity® is a fully integrated mobile fusion imaging platform designed for personalised prostate care. Uniquely equipped with 3D ultrasound probes and KOELIS® patented Organ-Based Tracking Fusion® technology, KOELIS Trinity® brings maximum...

New ultrasound imaging technique reliably spots prostate cancer, initial patient trial reveals

16 January 2025
A groundbreaking new imaging approach developed by researchers at Heriot-Watt University has shown ‘extremely encouraging’ results in early-stage clinical trials on prostate cancer at the Western General Hospital in Edinburgh, Scotland. The ongoing clinical trial demonstrated an initial 94% sensitivity...